Video Experimental Relacionado
Updated: Sep 9, 2025

09:06
Whole-brain Segmentation and Change-point Analysis of Anatomical Brain MRI—Application in Premanifest Huntington's Disease
Published on: June 9, 2018
12.2K
¿Qué tan pronto comienza la anosognosia en la enfermedad de Huntington?
Krisha Bagga1, Allen Xu1, Andrew Hall1
1Neurosciences, UC San Diego, La Jolla, CA, USA.
Movement disorders clinical practice
|September 1, 2025
Resumen
La anosognosia, o falta de conciencia de la enfermedad, está presente en las primeras etapas de la enfermedad de Huntington. Este hallazgo sugiere precaución cuando se utilizan datos autoinformados en la investigación clínica de la EH.
Área de la Ciencia:
- La neurociencia
- Neurología
- Investigación clínica
Sus antecedentes:
- La enfermedad de Huntington (HD) con frecuencia implica anosognosia, un déficit en la autoconciencia de las deficiencias.
- No se conoce con exactitud el inicio de la anosognosia durante la progresión de la EH.
Objetivo del estudio:
- Para determinar cuándo surge la anosognosia en personas con enfermedad de Huntington.
- Evaluar la presencia y ausencia de anosognosia en las diferentes etapas de la EH.
Principales métodos:
- La Escala de Anosognosia se administró a 60 portadores de genes de la enfermedad de Huntington y sus compañeros de estudio.
- Los participantes fueron estratificados utilizando el Sistema Integrado de Estadificación de la EH (HD-ISS), la Capacidad Funcional Total (TFC), el CAG-Age-Product (CAP) y la Escala Unificada de Clasificación de la Enfermedad de Huntington (cUHDRS).
- La anosognosia fue identificada por una diferencia de puntuación de ≥6 puntos entre los informes de pacientes e informantes.
Principales resultados:
- Se observó anosognosia en el 18% de los participantes en el estadio 0/1 de la EH-ISS.
- El 22% de los individuos con una puntuación de TFC de 13 exhibieron anosognosia.
- El 37% de los participantes elegibles para ensayos clínicos (puntuación CAP 400- 500) y el 23% con un cUHDRS ≥14 mostraron signos de anosognosia.
Conclusiones:
- La anosognosia es un síntoma temprano de la enfermedad de Huntington.
- El inicio temprano de la anosognosia indica la necesidad de limitar la dependencia de las medidas de autoinforme en los estudios clínicos de EH.
Videos de Conceptos Relacionados
Prosopagnosia
251
Prosopagnosia, also known as face blindness, is the inability to recognize faces. In severe cases, individuals with prosopagnosia may not recognize close family members, including parents and spouses, by their faces. For instance, someone with prosopagnosia might walk past their child in a crowd, only realizing their mistake upon noticing their child's distinctive backpack or favorite jacket. Prosopagnosia specifically impairs facial recognition, while the recognition of other objects or...
251
Visual Agnosia
298
Visual agnosia is a condition characterized by the inability to recognize visually presented objects despite having normal vision. For instance, a person with visual agnosia can describe the shape and color of an object but cannot identify or name it. This impairment does not affect their visual field, acuity, color vision, brightness discrimination, language, or memory. An example of this condition in a social setting is someone at a dinner party asking for "that silver thing with a round...
298
Alzheimer's Disease: Overview
666
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
666
Parkinson's Disease: Treatment
376
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
376
Parkinson's Disease: Overview
702
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
702
Alzheimer's Disease: Treatment
260
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
260

